<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECT: <z:hpo ids='HP_0001425'>Heterogeneous</z:hpo> mutations in the fibroblast growth factor receptor 2 gene (FGFR2) cause a range of <z:hpo ids='HP_0001363'>craniosynostosis</z:hpo> syndromes </plain></SENT>
<SENT sid="1" pm="."><plain>The specificity of the <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e>-affected cranial phenotype reflects its narrow mutational range: 98% of cases of <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e> result from an Ser252Trp or Pro253Arg mutation in the immunoglobulin-like (Ig)IIIa extracellular subdomain of FGFR2 </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast, a broad range of mutations throughout the extracellular domain of FGFR2 causes the overlapping cranial phenotypes of Pfeiffer and <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon syndromes</z:e> and related <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">craniofacial dysostoses</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: In this paper the expression of FGFR1, the IgIIIa/c and IgIIIa/b isoforms of FGFR2, and FGFR3 is investigated in <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e> (P253R mutation)- and Pfeiffer syndrome (C278F mutation)-affected fetal cranial tissue and is contrasted with healthy human control tissues </plain></SENT>
<SENT sid="4" pm="."><plain>Both FGFR1 and FGFR3 are normally expressed in the differentiated osteoblasts of the periosteum and osteoid, in domains overlapped by that of FGFR2, which widely include preosseous cranial mesenchyme </plain></SENT>
<SENT sid="5" pm="."><plain>Expression of FGFR2, however, is restricted to domains of advanced osseous differentiation in both <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e>- and Pfeiffer syndrome-affected cranial skeletogenesis in the presence of fibroblast growth factor (FGF)2, but not in the presence of FGF4 or FGF7 </plain></SENT>
<SENT sid="6" pm="."><plain>Whereas expression of the FGFR2-IgIIIa/b (KGFR) isoform is restricted in <z:mpath ids='MPATH_458'>normal</z:mpath> human cranial osteogenesis, there is preliminary evidence that KGFR is ectopically expressed in Pfeiffer syndrome-affected cranial osteogenesis </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Contraction of the FGFR2-IgIIIa/c (BEK) expression domain in cases of <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e>- and Pfeiffer syndrome-affected fetal cranial ossification suggests that the mutant activation of this receptor, by ligand-dependent or ligand-independent means, results in negative autoregulation </plain></SENT>
<SENT sid="8" pm="."><plain>This phenomenon, resulting from different mechanisms in the two syndromes, offers a model by which to explain differences in their cranial phenotypes </plain></SENT>
</text></document>